Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | NQO2 | P16083 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PRNP | P04156 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20836401 | 0.90 | MAPT (0.50) | TSHRSMN1; SMN2TAAR1MAPTNPSR1 | |
| SCHEMBL31483694 | 0.90 | MAPT (0.50) | TSHRSMN1; SMN2TAAR1MAPTNPSR1 | |
| SCHEMBL16167828 | 0.87 | L3MBTL1 (0.56) | SMN1; SMN2TAAR1MAPTNPSR1NQO2 | |
| SCHEMBL1505362 | 0.87 | MAPT (0.52) | TSHRSMN1; SMN2TAAR1MAPTNPSR1 | |
| SCHEMBL10122740 | 0.85 | TSHR (0.47) | TSHRSMN1; SMN2TAAR1MAPTNPSR1 | |
| SCHEMBL15031974 | 0.85 | MAPT (0.50) | TAAR1MAPTNPSR1NQO2L3MBTL1 | |
| SCHEMBL3297985 | 0.85 | GRIN2D (0.45) | SMN1; SMN2TAAR1MAPTNPSR1NQO2 | |
| SCHEMBL12957756 | 0.85 | NQO2 (0.48) | TAAR1MAPTNPSR1NQO2L3MBTL1 | |
| SCHEMBL2954181 | 0.84 | TAAR1 (0.56) | SMN1; SMN2TAAR1MAPTL3MBTL1POLB | |
| SCHEMBL2862226 | 0.82 | L3MBTL1 (0.50) | SMN1; SMN2TAAR1MAPTNPSR1NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025070947-A1 | NOVEL PHTHALAZINE DERIVATIVE COMPOUND AS SOS1 INHIBITOR, AND USE THEREOF | 한미약품 주식회사 | 2025-04-03 | — | — | WO | disclosed |
| WO-2020038464-A1 | FIBRIC ACID COMPOUND AND MEDICAL USE THEREOF | 北京厚燊药德科技有限责任公司 | 2020-02-27 | — | — | WO | disclosed |
| EP-1966842-B1 | Lighting elements and devices | LOMOX LTD (GB) | 2019-08-28 | — | — | EP | disclosed |
| WO-2018089261-A2 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | CORVUS PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| US-20170368051-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-28 | — | — | US | disclosed |
| US-9371318-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-06-21 | — | — | US | disclosed |
| US-20150133491-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-05-14 | — | — | US | disclosed |
| US-8987299-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-03-24 | — | — | US | disclosed |
| US-20140161736-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A (IT) | 2014-06-12 | — | — | US | disclosed |
| US-20120171111-A1 | PROCESS FOR PRODUCTION OF OXIDATION REACTION PRODUCT OF AROMATIC COMPOUND | OSAKA UNIVERSITY (JP) | 2012-07-05 | — | — | US | disclosed |
| US-6323373-B1 | USED TO OBTAIN POLYMERS WHICH ARE USED AS ELECTROLUMINESCENCE MATERIALS | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) | 2001-11-27 | — | — | US | disclosed |
| EP-1066250-A2 | A CONVERGENT SYNTHESIS OF ALPHA-ARYL-BETA KETONITRILES | Du Pont Pharmaceuticals Company (US) | 2001-01-10 | — | — | EP | disclosed |
| EP-1029019-A1 | SUBSTITUTED POLY(ARYLENE VINYLENES), METHOD FOR PRODUCING THE SAME, AND THEIR USE IN ELECTROLUMINESCENT ELEMENTS | Axiva GmbH (DE) | 2000-08-23 | — | — | EP | disclosed |
| US-6107508-A | SYNTHETIC INTERMEDIATES IN THE PREPARATION OF A SERIES OF BIOLOGICALLY IMPORTANT MOLECULES SUCH AS CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-08-22 | — | — | US | disclosed |
| WO-1999051568-A2 | A CONVERGENT SYNTHESIS OF α-ARYL-β-KETONITRILES | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-10-14 | — | — | WO | disclosed |
| EP-0944663-A1 | ARYL-SUBSTITUTED POLY(p-ARYLENE VINYLENES), METHOD FOR THE PRODUCTION AND USE THEREOF IN ELECTROLUMINESCENT COMPONENTS | Celanese Ventures GmbH (DE) | 1999-09-29 | — | — | EP | disclosed |
| EP-0944569-A1 | POLYMERIZABLE BIARYLS, METHOD FOR THE PRODUCTION AND USE THEREOF | Aventis Research & Technologies GmbH & Co. KG (DE) | 1999-09-29 | — | — | EP | disclosed |
| WO-1999024526-A1 | SUBSTITUTED POLY(ARYLENE VINYLENES), METHOD FOR PRODUCING THE SAME, AND THEIR USE IN ELECTROLUMINESCENT ELEMENTS | AXIVA GMBH (DE) | 1999-05-20 | — | — | WO | disclosed |
| WO-1998027136-A1 | ARYL-SUBSTITUTED POLY(p-ARYLENE VINYLENES), METHOD FOR THE PRODUCTION AND USE THEREOF IN ELECTROLUMINESCENT COMPONENTS | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO KG (DE) | 1998-06-25 | — | — | WO | disclosed |
| WO-1998025874-A1 | POLYMERIZABLE BIARYLS, METHOD FOR THE PRODUCTION AND USE THEREOF | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO KG (DE) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120171111-A1 | PROCESS FOR PRODUCTION OF OXIDATION REACTION PRODUCT OF AROMATIC COMPOUND | TYR, AOX1, POR | TSHR 4382/4885SMN1; SMN2 4595/4885TAAR1 1255/4885 |
| US-20170368051-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | MAVS, EIF2AK2, POLRMT | TSHR 4860/4885SMN1; SMN2 4230/4885TAAR1 4771/4885 |
| US-20140161736-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | TSHR 221/4885SMN1; SMN2 2305/4885TAAR1 119/4885 |
| US-20150133491-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | TSHR 221/4885SMN1; SMN2 2305/4885TAAR1 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.